Navigation Links
Finding may explain anti-cancer activity of thiazole antibiotics
Date:8/11/2009

University of Illinois at Chicago College of Medicine researchers have discovered how some recently approved drugs act against cancer cells. The finding may lead to a more effectively targeted anti-cancer strategy.

In a new study reported in the journal PLoS ONE online, UIC researchers show how a class of drugs inhibits a protein called FoxM1 and suggest that the drugs' ability to inhibit FoxM1 may account for their anti-cancer activity.

FoxM1 is one of the most highly over-produced proteins in cancer cells and is believed to play an important role is causing cells to become cancerous. Because production of the protein is not usually switched on in non-dividing cells, the protein may present a promising target for anti-cancer treatments.

Andrei Gartel, UIC associate professor of molecular genetics, and his colleagues had previously shown that antibiotics called thiazoles kill cancer cells and inhibit FoxM1. When they went on to investigate whether the antibiotics attacked other proteins involved in cancer, they got a surprising result.

"We found that these thiazole antibiotics actually stabilized other cancer-causing proteins," Gartel said.

It was an unexpected hint suggesting that thiazole antibiotics may act as inhibitors of the proteasome, a molecular complex that acts as a trash collector in cells, degrading old proteins that the cell has marked for destruction. This inhibition of the proteasome was confirmed in later experiments, Gartel said.

Recently, a number of proteasome inhibitors have shown promise against cancer, but no one understands why they have anti-cancer effects.

"We decided to see if these proteasome inhibitors, including Velcade, were, like our antibiotics, targeting FoxM1," he said.

The researchers found that the proteasome inhibitors did inhibit FoxM1 and that they also caused cells to self-destruct in the same concentrations.

It's possible, Gartel suggested, that by using thiazole antibiotics in combination with well-known proteasome inhibitors, "we may see a synergy that allows us to markedly reduce the dose of any one of these drugs and still effectively kill the cancer cells."


'/>"/>

Contact: Jeanne Galatzer-Levy
jgala@uic.edu
312-996-1583
University of Illinois at Chicago
Source:Eurekalert

Related medicine news :

1. Many Parents Share Genetic Test Findings With Kids
2. New Alzheimers findings: High stress and genetic risk factor lead to increased memory decline
3. New MRI finding sheds light on multiple sclerosis disease progressio
4. High and mighty: first common height gene identified by researchers behind obesity gene finding
5. Scientists, physicians present latest findings in personalized cancer treatment and prevention
6. Health psychologists discuss latest research findings
7. Incidental findings found when radiologists take a broader look at renal MRA
8. First significant genetic finding in severe PMS, or PMDD
9. Chair of U.S. Preventive Services Task Force Pledges to Recommend Re-evaluation of Recent Glaucoma Findings
10. The Organic Trade Association Hails Preliminary Research Findings Showing Nutritional Benefits of Organic Products
11. Key findings for all veterans seen in depression and suicide study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... ... October 12, 2017 , ... ... treating sleep apnea using cutting-edge Oventus O2Vent technology. As many as ... disorder characterized by frequent cessation in breathing. Oral appliances can offer significant relief ...
(Date:10/12/2017)... ... 2017 , ... IsoComforter, Inc. ( https://isocomforter.com ), one of the ... new design of the shoulder pad. The shoulder pad provides optimal support and ... pain while using cold therapy. By utilizing ice and water that is circulated from ...
(Date:10/12/2017)... ... 2017 , ... Information about the technology: , Otomagnetics has ... prevention of a major side effect of chemotherapy in children. Cisplatin and carboplatin ... cisplatin, hearing loss is FDA listed on-label as a dose limiting toxicity. Hearing ...
(Date:10/12/2017)... D.C. (PRWEB) , ... October 12, 2017 , ... Leading ... their peers in Washington, D.C., for the 49th Congress of the International Society ... ., Vice President of the Center for Cancer and Blood Disorders at ...
(Date:10/12/2017)... ... ... Health Literacy Innovations (HLI), creator of the Health Literacy ... Patient Education Network (CPEN), an independent professional organization that shares best practices in ... , As CPEN’s strategic partner, HLI will help support CPEN members by sharing ...
Breaking Medicine News(10 mins):
(Date:10/7/2017)... IRVING, Texas , Oct. 6, 2017   ... industry with more than $100 billion in purchasing power, ... industry news and information. The Newsroom is ... chain and industry trends, infographics, expert bios, news releases, ... Besides having access to a wealth of resources at ...
(Date:10/4/2017)... Mass. , Oct. 4, 2017 ... of single-use, self-contained, illuminating medical devices, today announced ... National Health Surveillance Agency (or Agência Nacional de ... The first single-use, cordless surgical retractor with integrated ... provides optimal access, illumination and exposure of a ...
(Date:10/2/2017)... , Oct. 2, 2017 Halo Labs announces the European ... system called the HORIZON at MIBio 2017 in Cambridge, ... and visible particulate matter in biopharmaceutical samples with unprecedented speed and ... the novel technique Backgrounded Membrane Imaging. ... The HORIZON subvisible particle analysis system ...
Breaking Medicine Technology: